Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination immunization regimen consisting of three separate vaccines: - **Comvax** is a bivalent vaccine containing Haemophilus influenzae type b capsular polysaccharide conjugated to Neisseria meningitidis outer membrane protein complex (OMPC), combined with hepatitis B surface antigen produced by recombinant yeast cultures. It provides protection against invasive diseases caused by *Haemophilus influenzae* type b and hepatitis B virus[1]. - **Infanrix** is a noninfectious, sterile combination vaccine containing diphtheria toxoid, tetanus toxoid, and acellular pertussis antigens (pertussis toxin [PT], filamentous hemagglutinin [FHA], pertactin). It induces immunity against diphtheria, tetanus, and pertussis[2][3][7][8]. - **Inactivated poliomyelitis vaccine** contains purified inactivated poliovirus types 1, 2, and 3 to induce immunity against polio infection[5][6]. The mechanism of action for all components involves stimulating the immune system to produce antibodies specific to each pathogen or toxin component included.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Comvax + Infanrix + inactivated poliomyelitis vaccine.